Reschke lab

Many thanks for sharing! :)

#postdoc | Health + Life Science Alliance Two more great interinstitutional #Postdoc positions at our Health + Life Science Alliance institutions. Read the complete post by PD Dr. Robin Reschke to find out the details. Deadline for applicati...

Two more great #Postdoc positions at our Alliance institutions.
Read the LinkedIn post by PI Robin Reschke to find out more.
Deadline for our postdoc call is March 31, 2026.
@embl.org @dkfz.bsky.social @ukhd.bsky.social

👉 Interesse am Thema Hautkrebs? Ich freue mich, wenn Sie vorbeikommen und sich mit mir austauschen.

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma Background Immune checkpoint inhibitors have transformed melanoma therapy but frequently cause immune-related adverse events (irAEs), including colitis, that limit treatment. Reliable biomarkers predi...

🧪✨ Can we predict immunotherapy toxicity before treatment starts?

Our new study says: yes.
Baseline autoantibody profiles predict irAEs & colitis in melanoma—and differ by PD-1 vs CTLA-4 therapy.

Toward safer, personalized checkpoint inhibition.

Open access 🚀:
jitc.bmj.com/content/14/1...

Fully funded Post-Doc @Heidelberg 🏰
Interested in cutting edge spatial biology methods 🗺️, computational biology 💻, cancer neuroscience 🧬, microbiome 🦠 and tumor immunology are encouraged to apply for projects 22 and 29.
You can directly apply with me🤩

www.health-life-sciences.de/opportunitie...

We invite applications for fully funded inter-institutional postdoctoral positions hosted by DKFZ, EMBL, the University of Heidelberg, and other. Interested candidates are encouraged to apply to projects 22 and 29 and others 😜

www.health-life-sciences.de/opportunitie...

YouTube video by OncoDaily TV ONCOFFEE: Robin Reschke – From Side Research to Leading a Lab, with Immunotherapy at the Core

New podcast alert🚨✨it was nice to take a moment at the end of the year to reflect on the past, both professionally and personally. 🎄If anyone is looking for a new podcast to listen to over the Christmas days, OnCoffee is definitely worth tuning into. youtu.be/vYEbOV4CP7M?...

🌊 HARPOON Conference 2025 — PREDICT Study 🎯

Happy to play a small part in this high-quality DKFZ/DKTK/NCT meeting and to share our latest results from the PREDICT study, which I’m proud to co-lead with Prof. Jessica Hassel.

#HARPOON #DKFZ #DKTK #NCT #immunotherapy #cancercoreeurope #melanoma

Portugal’s Golden Gate Bridge 🤩

✨ Grateful for the opportunity to present some data from my lab today at #EACR2025 in Lisbon! 🧬🔬🇵🇹
It was a pleasure to engage with such an inspiring community of researchers.💡🙌 Thanks to everyone who stopped by, asked questions, and shared ideas — exciting things ahead! 🚀
@helloeacr.bsky.social

First time at #EACR — excited to kick off this incredible meeting in beautiful Lisbon! Let the science (and sunshine) begin ☀️🇵🇹
@EACRnews #Lisboa #EACR2025 @helloeacr.bsky.social

Feeling very grateful! 🤩🎉
A heartfelt thank you to my amazing MD students for the kind congratulations on my successful habilitation as Privatdozent (Priv.-Doz.) 🐥🎓 😁

Thank you! It was an amazing first SID meeting for me :)

Stellar Keynote lecture from Laura Mackay on TRM cell fate at #SID25 in San Diego @siderm.bsky.social 🤓🤩🎉

Great experience and stellar scientific meeting 😊

Big thanks to the Society for Investigative Dermatology for an amazing meeting in San Diego so far! Honored to receive an award for our work and the invitation to present 🥳Grateful for the inspiring science, conversations, and community! ☀️#SID2025#DermResearch 
@siderm.bsky.social

Auftakt für TRYTRAC, das europäische Nachwuchsprogramm von Cancer Core Europe (CCE): Junge Wissenschaftler:innen aus sieben Top-Krebszentren – darunter vier Fellows aus Heidelberg – trafen sich am Karolinska Institutet in Stockholm.
🔗 www.nct-heidelberg.de/das-nct/news...

Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities

Recommended 📖 “Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities” @natureportfolio.nature.com co-authored by @drrobinreschke.bsky.social from @nct-heidelberg.bsky.social @dkfz.bsky.social
🔗 www.nature.com/articles/s41...

Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities

www.nature.com/articles/s41...

Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities

🚨New research highlight: study on managing immunotherapy side effects without weakening anti-tumor power!
ECP reduces harmful immune activity via neutrophils/T cells & promotes M2 macrophages via adiponectin.
Promising results from Zeiser et al. 🔬 🧪 🧫
Full summary:
www.nature.com/articles/s41...

Thanks for sharing our manuscript @cancercoreeurope.bsky.social 🎉

📖 “Targeting molecular pathways to control immune checkpoint inhibitor toxicities” co-authored by @drrobinreschke.bsky.social  from @nct-heidelberg.bsky.social  @dkfz.bsky.social 

🔗 https://www.cell.com/trends/immunology/fulltext/S1471-4906(24)00299-0

Heidelberg is placing first when it comes to #startup founders per capita in #Germany. With 13.5 new startups per 100.000 inhabitants in 2024, Heidelberg is outperforming startup hotspots such as #Berlin and #Munich.
The full report is here:
startupverband.de/fileadmin/st...

Now featured and OPEN ACCESS 💫👏🏻🚀

The article is now featured and OPEN ACCESS 💫

The article is now featured and OPEN ACCESS 💫

Targeting molecular pathways to control immune checkpoint inhibitor toxicities Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but are frequently associated with immune-related adverse events (irAEs). This article offers a novel synthesis of findings from b...

The article is now featured and OPEN ACCESS 💫👏🏻

www.cell.com/trends/immun...

Targeting molecular pathways to control immune checkpoint inhibitor toxicities - OncoDaily Targeting molecular pathways to control immune checkpoint inhibitor toxicities / Alexander H. Enk, cancer, cancer treatment, Evan J Lipson, Harvard

Targeting molecular pathways to control immune checkpoint inhibitor toxicities
@drrobinreschke.bsky.social
@jhu.edu @harvard.edu

oncodaily.com/science/immu...

#Cancer #CancerTreatment #ImmuneCheckpointBlockade #OncoDaily #Oncology #Medicine #Health

Thanks for sharing 😍